Oncolytics Biotech (TSE:ONC) Insider Buys C$11,400.00 in Stock

Oncolytics Biotech Inc. (TSE:ONC) insider Allison Hagerman purchased 10,000 shares of Oncolytics Biotech stock in a transaction dated Thursday, February 12th. The stock was bought at an average cost of C$1.14 per share, with a total value of C$11,400.00. Following the completion of the purchase, the insider owned 79,842 shares in the company, valued at approximately C$91,019.88. This trade represents a 14.32% increase in their position.

Oncolytics Biotech Price Performance

Oncolytics Biotech Inc. has a 52 week low of C$0.44 and a 52 week high of C$2.08. The company has a debt-to-equity ratio of 11.75, a current ratio of 2.99 and a quick ratio of 8.86. The firm has a market cap of C$1.50 billion, a PE ratio of -40.27 and a beta of 0.80. The stock has a 50-day simple moving average of C$14.90 and a 200 day simple moving average of C$13.02.

Oncolytics Biotech (TSE:ONC) last issued its quarterly earnings data on Wednesday, November 12th. The company reported C($0.14) earnings per share (EPS) for the quarter. As a group, equities research analysts forecast that Oncolytics Biotech Inc. will post -0.41 EPS for the current fiscal year.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.